Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,717.20
(
1.51%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.50
(
-0.19%
)
Bitcoin
79,456.21
(
0.22%
)
News Focus
News Focus
Post# of 257556
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 159024

Saturday, 06/22/2013 6:38:05 PM

Saturday, June 22, 2013 6:38:05 PM

Post# of 257556
ABBV/ENTA will start a phase-1 trial of ABT-493 (ENTA’s next-gen PI, which is licensed to ABBV) + ABT-530 (ABBV’s own next-generation NS5A) in 3Q13. Unlike ABT-450, ABT-493 does not require ritonavir boosting and it is small enough to be combined with ABT-530 in a single qD tablet.

The combination may have utility beyond genotype-1, although the companies have not yet made specific claims. (Source: ENTA’s recent WF webcast.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today